Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Evelo Biosciences Inc

(NASDAQ: EVLO)
Add to Portfolio
-0.16 (-2.39%)
as of Oct 18, 2019

Last 6.53
Change -0.16 (-2.39%)
Open 6.61
Prev. Close 6.69
Today's Range
6.47
6.62
52wk Range
4.90
15.89
Volume 33,900
Avg Volume 46,110
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
EVLO -2.39% +11.24% -34.63%
DJIA -0.95% +1.49% +5.48%
S&P 500 -0.39% +1.64% +7.85%

Key Statistics

Annual EPS -2.28
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 214,480
Weighted Alpha -48.50
Standard Deviation -0.65
Profit Margin N/A
Beta -0.17

Growth Rates

YTD -49.81%
1-Year -32.05%

Opinion

Sell Hold Buy

Recent Headlines

Evelo Biosciences to Present at the 2019 Cantor Global

GlobeNewswire via COMTEX - Thu Sep 26, 04:05PM EDT
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the 2019 Cantor Global (full story)
EVLO: 6.53 (-0.16)

Evelo Biosciences to Host Key Opinion Leader Symposium

GlobeNewswire via COMTEX - Fri Sep 20, 07:00AM EDT
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it will host a key opinion leader symposium on the unmet need in mild (full story)
EVLO: 6.53 (-0.16)

Evelo Biosciences Announces the Appointment of David

GlobeNewswire via COMTEX - Tue Sep 17, 07:01AM EDT
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, announced today that David Epstein has been appointed chairman of its Board of Directors. M(full story)
EVLO: 6.53 (-0.16)

Evelo Biosciences to Present at the Morgan Stanley

GlobeNewswire via COMTEX - Wed Sep 04, 07:27PM EDT
Evelo Biosciences, Inc. (Nasdaq:EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that management will participate in a fireside ch(full story)
MS: 43.66 (+0.22), EVLO: 6.53 (-0.16)

Evelo Biosciences Reports Positive EDP1815 Interim

GlobeNewswire via COMTEX - Tue Aug 06, 07:05AM EDT
-EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo-(full story)
EVLO: 6.53 (-0.16)